Description of the protocols for randomized controlled trials on cancer drugs conducted in Spain (1999-2003)

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Bonfill, Xavier ^a,b,c   Ballesteros, Mónica ^a,c   Gich, Ignasi ^a,b,c   Serrano, María Antonia ^d   Garciá López, Fernando ^e   Urrut́ia, Gerard ^a,b  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Agencia Espanola de Medicamentos y Productos Sanitarios   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; PACLITAXEL; PREDNISONE; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BREAST CANCER; CLINICAL PROTOCOL; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LYMPHOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SPAIN;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL PROTOCOLS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 84893352424     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079684     Document Type: Article

References (28)

1. Chan AW (2008) Bias, spin, and misreporting: time for full access to trial protocols and results. PLOS Med 5: e230. doi:10.1371/journal.pmed.0050230. PubMed: 19067481.
2. Ministerio de Sanidad y Consumo (1993) Real Decreto 561/93 del 6 de abril por el que se establecen los requisitos para la realización de ensayos clínicos con medicamentos. Boletín Oficial del Estado pp. 14346-14364.
3. Rasmussen N, Lee K, Bero L (2009) Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials 10: 116. doi:10.1186/1745-6215-10-116. PubMed: 20015404.
4. Sim I, Chan AW, Gülmezoglu AM, Evans T, Pang T (2006) Clinical trial registration: transparency is the watchword. Lancet 367: 1631-1633. doi:10.1016/S0140-6736(06)68708-4. PubMed: 16714166. (Pubitemid 43728234)
5. Lefebvre C, Eisinga A, McDonald S, Paul N (2008) Enhancing access to reports of randomized trials published worldwide the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library. Emerg Themes Epidemiol 5: 13. doi:10.1186/1742-7622-5-13. PubMed: 18826567.
6. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J et al. (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 364: 911-912. doi:10.1016/S0140-6736(04)17034-7. PubMed: 15364170.
7. Tetzlaff JM, Chan AW, Kitchen J, Sampson M, Tricco AC et al. (2012) Guidelines for randomized clinical trial protocol content: a systematic review. Syst Rev 1: 43. doi:10.1186/2046-4053-1-43. PubMed: 23006870.
8. Tetzlaff JM, Moher D, Chan AW (2012) Developing a guideline for clinical trial protocol content: Delphi consensus survey. Trials 13: 176. doi:10.1186/1745-6215-13-176. PubMed: 23006145.
9. Garcia Lopez FJ (1993) [Impact of legal regulations on the quality of clinical trials carried out in Spain]. Med Clin (Barc) 100: 770-777.
10. Soto J, Galende I, Sacristan JA (1994) The quality of clinical trials published in Spain: an evaluation by an analysis of 3 journals during the 1985-1991 period. Med Clin (Barc) 102: 241-245.
11. Carcas AJ, Serrano MA, Avendano C, Galende I, Tristan C et al. (1995) Clinical trials with drugs: the influence of the authorization process. Med Clin (Barc) 104: 683-688.
12. Dickersin K, Garcia-Lopez F (1992) Regulatory process effects clinical trial registration in Spain. Control Clin Trials 13: 507-512. doi:10.1016/0197-2456(92)90207-G. PubMed: 1334822. (Pubitemid 23001798)
13. Organization WHO (2006)ew standards for registration of human medical research; World Health Organization International Clinical Trials Registry Geneva.
14. Weinstein IB, Case K (2008) The history of Cancer Research: introducing an AACR Centennial series. Cancer Res 68: 6861-6862. doi:10.1158/0008-5472.CAN- 08-2827. PubMed: 18757396.
15. Serrano Castro MA, Labrador Canadas MV, Gonzalez Colaco C, Vargas Castrillon E (2010) Clinical trials on drugs authorized in Spain during 2007 and 2008. Med Clin (Barc) 134: 316-322. doi:10.1016/j.medcli.2009.05.024.
16. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH et al. (2012) Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 307: 1838-1847. doi:10.1001/jama.2012.3424. PubMed: 22550198.
17. Pich J, Carné X, Arnaiz JA, Gómez B, Trilla A et al. (2003) Role of a research ethics committee in follow-up and publication of results. Lancet 361: 1015-1016. doi:10.1016/S0140-6736(03)12799-7. PubMed: 12660062. (Pubitemid 36351372)
18. Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A (2012) Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol 65: 602-609. doi:10.1016/j.jclinepi.2011.10.016. PubMed: 22424985.
19. Espinosa E, Zamora P, Gonzalez Baron M (1999) An outlook on the future in oncology research in Spain. Med Clin (Barc) 113: 541-543.
20. Soares HP, Daniels S, Kumar A, Clarke M, Scott C et al. (2004) Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ 328: 22-24. doi:10.1136/bmj.328.7430.22. PubMed: 14703540. (Pubitemid 38067738)
21. Soares HP, Kumar A, Daniels S, Swann S, Cantor A et al. (2005) Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA 293: 970-978. doi:10.1001/jama.293.8.970. PubMed: 15728168. (Pubitemid 40271129)
22. Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G et al. (2008) Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med 168: 632-642. doi:10.1001/archinte.168.6.632. PubMed: 18362256. (Pubitemid 351468398)
23. Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S et al. (2013) Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLOS ONE 8: e58711. doi:10.1371/journal.pone.0058711. PubMed: 23555593.
24. Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T et al. (2012) New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev 10: MR000024. PubMed: 23076962.
25. Dwan K, Gamble C, Williamson PR, Altman DG (2008) Reporting of clinical trials: a review of research funders' guidelines. Trials 9: 66. doi:10.1186/1745-6215-9-66. PubMed: 19032743.
26. Alltrials website. Available: http://www.alltrials.net/#sthash.wfFLdJhb. dpbs. Accessed 2013 February 10
27. Gøtzsche PC (2012) Deficiencies in proposed new EU regulation of clinical trials. BMJ 345: e8522. doi:10.1136/bmj.e8522. PubMed: 23258926.
28. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC et al. (2013) SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med 158: 200-207. doi:10.7326/0003-4819-158-3-201302050- 00583. PubMed: 23295957.